Supplemental Material

Table S1. Estimated outcomes with blood-based and stool-based test under various adherence and blood-based test adenoma sensitivity scenarios.

Screening Test	Adherence	Total COLs	CRC cases	CRC deaths	LY with CRC	LYG	CRC incidence reduction	CRC mortality reduction
No screening		80.1	80.1	36.8	643.1	0.000	0.0%	0.0%
	30%	1084.2	40.1	15.5	402.8	248.1	50.0%	57.8%
	40%	1208.4	36.6	13.9	375.1	269.1	54.3%	62.2%
	50%	1299.0	34.3	12.8	356.2	284.1	57.2%	65.3%
mt-sDNA	60%	1371.7	32.6	12.0	343.1	292.6	59.3%	67.4%
	70%	1428.2	31.4	11.4	332.4	299.6	60.8%	68.9%
	100%	1546.9	28.9	10.3	311.3	313.2	64.0%	71.9%
	RW	1404.5	31.9	11.7	334.5	297.1	60.2%	68.1%
	30%	811.4	46.7	18.2	466.4	220.2	41.8%	50.5%
	40%	972.7	40.8	15.3	424.9	254.2	49.1%	58.4%
	50%	1102.8	36.7	13.3	391.3	278.8	54.3%	63.8%
FIT	60%	1229.3	33.2	11.8	361.9	295.8	58.5%	68.0%
	70%	1321.5	30.9	10.9	339.6	308.1	61.5%	70.5%
	100%	1585.5	25.6	8.7	286.9	333.1	68.0%	76.2%
	RW	1004.9	39.8	14.9	419.2	258.9	50.3%	59.6%
	30%	647.0	57.2	22.6	562.8	174.5	28.6%	38.7%
	40%	794.6	52.1	19.7	534.4	206.4	35.0%	46.5%
	50%	923.9	47.7	17.5	507.1	232.3	40.5%	52.3%
FOBT	60%	1040.4	44.1	15.6	485.1	256.6	44.9%	57.6%
	70%	1148.8	40.8	14.2	457.0	273.9	49.0%	61.3%
	100%	1426.6	33.8	11.2	392.8	306.6	57.8%	69.5%
	RW	698.3	55.3	21.6	551.5	185.1	30.9%	41.4%
Dlag J C1	30%	820.6	60.0	24.3	576.1	151.3	25.1%	34.0%
Blood, S1	40%	938.5	57.0	22.5	563.0	172.9	28.9%	38.9%

-	•	•						
nAAS=10% AAS=10%	50%	1030.0	54.6	21.2	548.5	188.1	31.9%	42.3%
AAD-IV/U	60%	1099.6	53.0	20.3	541.7	199.6	33.9%	44.9%
	70%	1157.2	51.7	19.6	535.7	208.0	35.5%	46.7%
	100%	1285.8	48.7	17.9	519.1	227.5	39.2%	51.3%
	30%	920.4	54.0	21.9	523.3	175.0	32.6%	40.6%
	40%	1043.3	50.8	20.0	506.8	197.9	36.6%	45.6%
Blood, S2 nAAS=12.5%	50%	1146.0	48.1	18.6	487.9	214.4	40.0%	49.4%
AAS=12.5% AAS=15%	60%	1216.9	46.5	17.8	479.3	224.5	42.0%	51.7%
	70%	1275.4	44.8	16.8	468.1	235.8	44.1%	54.2%
	100%	1405.9	41.7	15.3	447.3	253.8	48.0%	58.4%
	30%	967.2	52.3	21.1	509.2	183.4	34.7%	42.7%
	40%	1101.9	48.5	19.1	487.0	206.8	39.5%	48.0%
Blood, S3	50%	1194.8	46.1	17.9	471.0	221.6	42.5%	51.4%
nAAS=15% AAS= 15%	60%	1268.3	43.9	16.8	456.0	234.1	45.2%	54.5%
	70%	1339.8	42.3	16.0	445.9	242.9	47.2%	56.4%
	100%	1470.2	39.3	14.4	426.3	262.4	50.9%	60.8%
	30%	1003.7	49.1	19.8	479.1	196.4	38.7%	46.1%
	40%	1134.9	45.6	17.9	460.1	219.7	43.1%	51.4%
Blood, S4	50%	1239.0	43.0	16.7	439.5	234.4	46.3%	54.6%
nAAS=15% AAS= 20%	60%	1316.4	40.9	15.5	424.0	247.7	49.0%	57.8%
	70%	1369.6	39.5	14.9	414.3	256.3	50.7%	59.4%
	100%	1505.7	36.4	13.4	391.7	272.9	54.5%	63.7%
	30%	1089.2	45.5	18.2	451.3	212.5	43.2%	50.5%
	40%	1231.3	41.8	16.4	425.7	234.1	47.8%	55.5%
Blood, S5	50%	1334.8	39.1	15.0	407.3	250.4	51.2%	59.2%
nAAS=20% AAS= 20%	60%	1409.7	37.3	14.2	392.4	261.4	53.5%	61.5%
	70%	1472.6	35.7	13.4	380.2	270.2	55.4%	63.5%
	100%	1601.9	32.7	11.9	358.2	287.2	59.2%	67.6%
	L			CDC		T		

AAS, advanced adenoma (≥ 10 mm) sensitivity; COL, colonoscopy; CRC, colorectal cancer; FIT, fecal immunochemical test; FOBT, fecal occult blood test; LY, life-years; LYG, life-years gained; mt-sDNA, multi-target stool DNA; nAAS, non-advanced adenoma (<10 mm) sensitivity; RW, real-world; S, scenario.


Table S2. Estimated outcomes of sensitivity analyses with blood-based test under various adherence and expanded blood-based test adenoma sensitivity scenarios.

Blood-test sensitivity	Adherence	Total COLs	CRC cases	CRC deaths	LYG	CRC Incidence reduction	CRC Mortality reduction
	30%	1147.4	41.4	16.5	231.3	48.3%	55.1%
	40%	1279.0	37.7	14.7	252.6	53.0%	59.9%
nAAS=20%	50%	1382.9	35.0	13.5	268.5	56.4%	63.3%
AAS= 30%	60%	1462.4	33.0	12.6	278.8	58.8%	65.8%
	70%	1521.6	31.6	11.9	287.4	60.6%	67.7%
	100%	1647.9	29.0	10.9	300.7	63.8%	70.5%
	30%	1288.7	36.1	14.4	253.1	54.9%	60.8%
	40%	1426.9	32.3	12.6	272.6	59.7%	65.7%
nAAS=30%	50%	1526.3	29.9	11.5	287.9	62.7%	68.8%
AA= 30%	60%	1602.3	28.0	10.7	298.4	65.0%	71.0%
	70%	1665.2	26.9	10.1	305.6	66.4%	72.6%
	100%	1788.0	24.6	9.1	317.9	69.3%	75.2%
	30%	1263.3	35.3	14.2	256.7	55.9%	61.5%
	40%	1399.2	31.7	12.4	278.6	60.4%	66.3%
nAAS=25%	50%	1499.4	29.2	11.2	293.3	63.5%	69.5%
AAS= 40%	60%	1568.1	27.8	10.7	300.3	65.3%	71.0%
	70%	1629.4	26.7	10.1	307.5	66.7%	72.6%
	100%	1747.3	24.5	9.2	319.8	69.4%	75.1%
	30%	1430.8	29.5	11.8	281.9	63.2%	68.1%
	40%	1563.1	26.2	10.1	301.7	67.3%	72.4%
nAAS=40%	50%	1662.6	23.9	9.2	313.7	70.1%	74.9%
AAS= 40%	60%	1731.1	22.6	8.6	320.3	71.8%	76.5%
	70%	1790.6	21.8	8.2	325.9	72.8%	77.6%
	100%	1905.7	20.3	7.5	336.7	74.7%	79.5%

AAS, advanced adenoma (≥ 10 mm) sensitivity; COL, colonoscopy; CRC, colorectal cancer; LYG, life-years gained; nAAS, non-advanced adenoma (<10 mm) sensitivity.

Figure S1. Colorectal cancer incidence reduction (IR) per 1,000 patients screened over lifetime horizon based on different adherence rates blood-based test adenoma sensitivity at A) 10% and B) 20%. Numbers represent ranges of incremental IR versus the blood-based test. A positive value (green) indicates the stool-based test has less IR than the blood-based test, and a negative value (red/orange) indicates the stool-based test has more IR than the blood-based test. Adherence rates ranged from 100% or 30-70% for both stool- and blood-tests. FIT, fecal immunochemical test; FOBT, fecal occult blood test; mt-sDNA, multi-target stool DNA.

A)



B)

				mt-s	DNA								F	IT												
	Screening adherence rate	30%	40%	50%	60%	70%	100%	Blood IR		Screening adherence rate	30%	40%	50%	60%	70%	100%	Blood IR		Screening adherence rate	30%	40%	50%	60%	70%	100%	Blood IR
	30%	-7%	-11%	-14%	-16%	-18%	-21%	43%		30%	1%	-6%	-11%	-15%	-18%	-25%	43%		30%	15%	8%	3%	-2%	-6%	-15%	43%
	40%	-2%	-6%	-9%	-11%	-13%	-16%	48%		40%	6%	-1%	-6%	-11%	-14%	-20%	48%		40%	19%	13%	7%	3%	-1%	-10%	48%
Blood	50%	1%	-3%	-6%	-8%	-10%	-13%	51%	Blood	50%	9%	2%	-3%	-7%	-10%	-17%	51%	Blood	50%	23% 169	16%	11%	6%	2%	-7%	51%
Test	60%	4%	-1%	-4%	-6%	-7%	-10%	53%	Test	60%	12%	4%	-1%	-5%	-8%	-15%	53%	Test	60%	25%	18%	13%	9%	4%	-4%	53%
	70%	5%	1%	-2%	-4%	-5%	-9%	55%		70%	14%	6%	1%	-3%	-6%	-13%	55%		70%	27%	20%	15%	10%	6%	-2%	55%
	100%	9%	5%	2%	0%	-2%	-5%	59%		100%	17%	10%	5%	1%	-2%	-9%	59%		100%	31%	24%	19%	14%	10%	1%	59%
	mt-sDNA IR	50%	54%	57%	59%	61%	64%			FIT IR	42%	49%	54%	59%	61%	68%			FOBT IR	29%	35%	41%	45%	49%	58%	

Figure S2. Colorectal cancer mortality reduction (MR) per 1,000 patients screened over lifetime horizon based on different adherence rates for blood-based test adenoma sensitivity at A) 10% and B) 20%. Numbers represent ranges of incremental MR versus the blood-based test. A positive value (green) indicates the stool-based test has less MR than the blood-based test, and a negative value (red/orange) indicates the stool-based test has more MR than the blood-based test. Adherence rates ranged from 100% or 30-70% for both stool- and blood-tests. FIT, fecal immunochemical test; FOBT, fecal occult blood test; mt-sDNA, multi-target stool DNA.

A)

		mt-sDNA											FIT								F	ОВТ			
	Screening adherence rate	30% 40%	50%	60%	70%	100%	Blood MR		Screening adherence rate	30%	40%	50%	60%	70%	100%	Blood MR		Screening adherence rate	30%	40%	50%	60%	70%	100%	Blood MR
	30%	-24% -28%	-31%	-33%	-35%	-38%	34%		30%	-17%	-24%	-30%	-34%	-36%	-42%	34%		30%	-5%	-12%	-18%	-24%	-27%	-35%	34%
	40%	-19% -23%	-26%	-29%	-30%	-33%	39%		40%	-12%	-19%	-25%	-29%	-32%	-37%	39%		40%	0%	-8%	-13%	-19%	-22%	-31%	39%
Blood	50%	-16% -20%	-23%	-25%	-27%	-30%	42%	Blo	50%	-8%	-16%	-22%	-26%	-28%	-34%	42%	Blood	50%	4%	-4%	-10%	-15%	-19%	-27%	42%
Test	60%	-13% -17%	-20%	-22%	-24%	-27%	45%	Te	60%	-6%	-13%	-19%	-23%	-26%	-31%	45%	Test	60%	6%	-2%	-7%	-13%	-16%	-25%	45%
	70%	-11% -16%	-19%	-21%	-22%	-25%	47%		70%	-4%	-12%	-17%	-21%	-24%	-30%	47%		70%	8%	0%	-6%	-11%	-15%	-23%	47%
	100%	-7% -11%	-14%	-16%	-18%	-21%	51%		100%	1%	-7%	-13%	-17%	-19%	-25%	51%		100%	13%	5%	-1%	-6%	-10%	-18%	51%
	mt-sDNA MR	58% 62%	65%	67%	69%	72%			FIT MR	50%	58%	64%	68%	70%	76%			FOBT MR	39%	46%	52%	58%	61%	69%	

B)

				mt-s	sDNA								ı	FIT								F	ОВТ			
	Screening adherence rate	30%	40%	50%	60%	70%	100%	Blood MR		Screening adherence rate	30%	40%	50%	60%	70%	100%	Blood MR		Screening adherence rate	30%	40%	50%	60%	70%	100%	Blood MR
	30%	-7%	-12%	-15%	-17%	-18%	-21%	50%		30%	0%	-8%	-13%	-17%	-20%	-26%	50%		30%	12%	4%	-2%	-7%	- 11%	-19%	50%
	40%	-2%	-7%	-10%	-12%	-13%	-16%	55%		40%	5%	-3%	-8%	-12%	-15%	-21%	55%		40%	17%	9%	3%	-2%	-6%	-14%	55%
Blood	50%	1%	-3%	-6%	-8%	-10%	-13%	59%	Bloo	50%	9%	1%	-5%	-9%	-11%	-17%	59%	Blood	50%	20%	13%	7%	2%	-2%	-10%	59%
Test	60%	4%	-1%	-4%	-6%	-7%	-10%	62%	Test	60%	11%	3%	-2%	-6%	-9%	-15%	62%	Test	60%	23%	15%	9%	4%	0%	-8%	62%
	70%	6%	1%	-2%	-4%	-5%	-8%	63%		70%	13%	5%	0%	-4%	-7%	-13%	63%		70%	25%	17%	11%	6%	2%	-6%	63%
	100%	10%	5%	2%	0%	-1%	-4%	68%		100%	17%	9%	4%	0%	-3%	-9%	68%		100%	29%	21%	15%	10%	6%	-2%	68%
	mt-sDNA MR	58%	62%	65%	67%	69%	72%			FIT MR	50%	58%	64%	68%	70%	76%			FOBT MR	39%	46%	52%	58%	61%	69%	